CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
CytomX Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -676.5%. For fiscal 2025 it was -29.3%, against 18.1% the year before. The highest annual figure on record is 18.1% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -29.3% | −47.4 |
| FY2024 | Dec 31, 2024 | 18.1% | +24.5 |
| FY2023 | Dec 31, 2023 | -6.4% | +184.2 |
| FY2022 | Dec 31, 2022 | -190.6% | +120.4 |
| FY2021 | Dec 31, 2021 | -311.0% | −193.3 |
| FY2020 | Dec 31, 2020 | -117.7% | +408.2 |
| FY2019 | Dec 31, 2019 | -525.9% | −395.0 |
| FY2018 | Dec 31, 2018 | -130.9% | −66.3 |
| FY2017 | Dec 31, 2017 | -64.6% | +331.5 |
| FY2016 | Dec 31, 2016 | -396.1% | +34.4 |
| FY2015 | Dec 31, 2015 | -430.5% | +155.7 |
| FY2014 | Dec 31, 2014 | -586.3% | +1098.0 |
| FY2013 | Dec 31, 2013 | -1684.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1392.3% | −1127.9 |
| Q2 FY2026 | Jun 30, 2026 | -1677.1% | −1670.2 |
| Q1 FY2026 | Mar 31, 2026 | -191.8% | −236.2 |
| Q4 FY2025 | Dec 31, 2025 | -4213.0% | −4259.4 |
| Q3 FY2025 | Sep 30, 2025 | -264.4% | −276.7 |
| Q2 FY2025 | Jun 30, 2025 | -6.9% | +26.8 |
| Q1 FY2025 | Mar 31, 2025 | 44.4% | +16.3 |
| Q4 FY2024 | Dec 31, 2024 | 46.4% | +48.7 |
| Q3 FY2024 | Sep 30, 2024 | 12.3% | +0.5 |
| Q2 FY2024 | Jun 30, 2024 | -33.7% | −20.1 |
| Q1 FY2024 | Mar 31, 2024 | 28.1% | +52.2 |
| Q4 FY2023 | Dec 31, 2023 | -2.3% | +45.0 |
| Q3 FY2023 | Sep 30, 2023 | 11.8% | +278.4 |
| Q2 FY2023 | Jun 30, 2023 | -13.5% | +220.3 |
| Q1 FY2023 | Mar 31, 2023 | -24.1% | +330.6 |
| Q4 FY2022 | Dec 31, 2022 | -47.2% | +266.3 |
| Q3 FY2022 | Sep 30, 2022 | -266.5% | +71.3 |
| Q2 FY2022 | Jun 30, 2022 | -233.8% | +69.7 |
| Q1 FY2022 | Mar 31, 2022 | -354.7% | −69.2 |
| Q4 FY2021 | Dec 31, 2021 | -313.5% | +26.6 |
| Q3 FY2021 | Sep 30, 2021 | -337.8% | −0.0 |
| Q2 FY2021 | Jun 30, 2021 | -303.6% | +65.0 |
| Q1 FY2021 | Mar 31, 2021 | -285.5% | −273.8 |
| Q4 FY2020 | Dec 31, 2020 | -340.1% | +480.8 |
| Q3 FY2020 | Sep 30, 2020 | -337.8% | −97.7 |
| Q2 FY2020 | Jun 30, 2020 | -368.6% | −22.1 |
| Q1 FY2020 | Mar 31, 2020 | -11.7% | +44.5 |
| Q4 FY2019 | Dec 31, 2019 | -820.9% | −595.9 |
| Q3 FY2019 | Sep 30, 2019 | -240.1% | −54.8 |
| Q2 FY2019 | Jun 30, 2019 | -346.5% | −284.4 |
| Q1 FY2019 | Mar 31, 2019 | -56.2% | +54.0 |
| Q4 FY2018 | Dec 31, 2018 | -225.0% | −220.4 |
| Q3 FY2018 | Sep 30, 2018 | -185.3% | −139.6 |
| Q2 FY2018 | Jun 30, 2018 | -62.1% | +227.8 |
| Q1 FY2018 | Mar 31, 2018 | -110.2% | −36.3 |
| Q4 FY2017 | Dec 31, 2017 | -4.6% | +222.3 |
| Q3 FY2017 | Sep 30, 2017 | -45.7% | – |
| Q2 FY2017 | Jun 30, 2017 | -289.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -73.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -226.9% | – |
See a number that looks wrong?